



Cases from the Clinic: Focus on Endometrial Cancer

Clinical Brief #2 – Monitoring and Management of irAEs

References

Tweet 2 References:

Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Management of Immunotherapy-Related Toxicities (v2.2023). Updated May 9, 2023. Accessed May 22, 2023.

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. *J Clin Oncol*. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440

Additional References:

Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med*. 2023;288:2159-2170. doi:10.1056/NEJMoa2302312

O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. *J Clin Oncol*. 2022;40(7):752-761. doi:10.1200/JCO.21.01874

Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med*. 2023;388:2145-2158. doi:10.1056/NEJMoa2216334

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*. 2022;10(1):e003777. doi:10.1136/jitc-2021-003777

Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*. 2020;38(26):2981-2992. doi:10.1200/JCO.19.02627



Glossary

A, advanced
AE, adverse event
ASCO, American Society of Clinical Oncology
CV, cardiovascular
dMMR, mismatch repair deficient
EC, endometrial cancer
GI, gastrointestinal
IO, immunotherapy
irAE, immune-related adverse events
IRR, infusion-related reaction
MSI-H, microsatellite instability high
MSK, musculoskeletal
NCCN, National Comprehensive Cancer Network
pMMR, mismatch repair proficient
PPE, palmar-plantar erythrodysesthesia
R, recurrent
w/, with